CENESTIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CENESTIN (CENESTIN).
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and exerting effects on reproductive tissues, bone, cardiovascular system, and CNS.
| Metabolism | Hepatic metabolism via CYP3A4 to estrone and estriol; undergoes enterohepatic recirculation. |
| Excretion | Primarily renal, with approximately 90% excreted in urine as glucuronide and sulfate conjugates; about 10% excreted in feces via bile. |
| Half-life | Terminal elimination half-life is approximately 10-24 hours for conjugated estrogens; this long half-life allows for once-daily dosing and sustained estrogenic effects. |
| Protein binding | Approximately 50-80% bound, primarily to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Not well-defined in literature; due to lipophilicity, Vd is expected to be large (estimated 10-20 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Oral: Approximately 30-50% due to first-pass metabolism in the liver and gut. |
| Onset of Action | Oral: 2-4 hours for measurable estrogenic effects (e.g., vaginal maturation index changes). |
| Duration of Action | Oral: 24 hours, supporting once-daily administration; effects on vasomotor symptoms may persist for several days after discontinuation. |
0.45 mg orally once daily; titrate up to 1.25 mg once daily based on symptoms. Maximum dose 1.25 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment recommended for renal impairment; use with caution due to potential fluid retention. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and adjust if adverse effects occur. |
| Pediatric use | Safety and efficacy not established; not recommended for use in pediatric patients. |
| Geriatric use | Initiate at lowest dose (0.3-0.45 mg daily) due to increased risk of adverse effects; monitor for thromboembolic events and malignancy. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CENESTIN (CENESTIN).
| Breastfeeding | Excreted in human milk in small amounts; M/P ratio unknown. Estrogens may reduce milk production and quality. Not recommended for use during breastfeeding due to potential adverse effects in the infant and decreased milk supply. |
| Teratogenic Risk | Pregnancy category X. Use of Cenestin (conjugated estrogens) is contraindicated during pregnancy. Studies have shown increased risk of vaginal adenosis, cervical and vaginal cancer in female offspring exposed to diethylstilbestrol (a related estrogen) in utero. Estrogens should not be used during pregnancy as they are ineffective for threatened or habitual abortion. |
■ FDA Black Box Warning
Endometrial cancer: Unopposed estrogen increases risk of endometrial cancer in women with a uterus; addition of progestin is recommended. Cardiovascular disorders: Estrogen therapy increases risk of stroke and DVT; do not use for prevention of cardiovascular disease. Breast cancer: Estrogen plus progestin increases risk of invasive breast cancer; possibly increased risk with estrogen alone. Probable dementia: Estrogen therapy increases risk of probable dementia in postmenopausal women aged 65 years or older.
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia","Active DVT, PE, or history of these conditions","Active arterial thromboembolic disease or history (e.g., stroke, MI)","Known anaphylactic reaction or angioedema to CENESTIN","Known liver impairment or disease","Known or suspected pregnancy"]
| Precautions | ["Cardiovascular disorders (stroke, DVT, MI)","Malignant neoplasms (endometrial, breast, ovarian)","Gallbladder disease","Hypertriglyceridemia","Fluid retention","Hypocalcemia","Hereditary angioedema","Exacerbation of endometriosis","Impaired liver function","Excessive estrogen levels (e.g., due to liver disease)"] |
Loading safety data…
| Fetal Monitoring | Not applicable as drug is contraindicated in pregnancy; if unintentional exposure occurs, monitor for fetal effects with ultrasound for urogenital abnormalities. |
| Fertility Effects | May impair fertility by suppressing ovulation through negative feedback on hypothalamic-pituitary axis. Use can interfere with conception; reversible upon discontinuation. |
| Food/Dietary |
| Grapefruit juice may increase estrogen levels by inhibiting CYP3A4 metabolism. St. John's wort may reduce estrogen efficacy. Avoid excessive alcohol intake as it may increase estrogen levels and risk of adverse effects. |
| Clinical Pearls | Cenestin is a conjugated estrogens, synthetic A (CESA) product used for menopausal hormone therapy. It is bioidentical to estrogens found in pregnant mare's urine but synthesized from plant sources. Monitor for endometrial hyperplasia; unopposed estrogen increases risk of endometrial cancer. Use with a progestin in women with an intact uterus. Avoid use in women with a history of venous thromboembolism or estrogen-dependent tumors. |
| Patient Advice | Take exactly as prescribed; do not skip doses or stop abruptly without consulting your healthcare provider. · Report any signs of blood clots such as sudden chest pain, leg swelling, or shortness of breath. · Notify your doctor if you experience abnormal vaginal bleeding, breast lumps, or jaundice. · Cenestin does not prevent dementia; the Women's Health Initiative Memory Study reported increased risk of probable dementia in women over 65. · If you have a uterus, you may need to take a progestin along with Cenestin to reduce the risk of endometrial cancer. |